Shattuck Strikes Joint Development Deal With Japan's Ono Pharma
By Rob Curran
Shattuck Labs struck a joint-venture deal with Japanese drugmaker Ono Pharmaceutical to develop treatments for autoimmune and inflammatory diseases.
Shattuck, an Austin biotech concern with a laboratory in North Carolina, will receive an undisclosed up-front payment and be eligible for licensing, regulatory, and commercial milestone payments of up to $227 million, and further tiered sales-based royalties.
Under the deal, Shattuck will lead research on certain compounds directed toward targets selected by Ono from Shattuck's pipeline of bifunctional fusion proteins. Shattuck's line of product candidates are intended to treat autoimmune diseases and cancer.
Ono will pay Shattuck's research and development expenses. Shattuck's R&D expenses totaled $59.1 million in the first nine months of 2023.
Ono would later have an option to conduct further research and commercialization worldwide.
Write to Rob Curran at rob.curran@wsj.com
(END) Dow Jones Newswires
February 13, 2024 06:42 ET (11:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening in the Markets This Week
-
4 Top Dividend-Paying REIT Stock Picks
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
-
P-CAPE: A Better Way for Investors to Estimate Future Returns
-
Which Stocks Have Driven the Stealth Large-Value Rally?
-
Forecasts for Q2 GDP Report Show a Healthy but Slowing Economy
-
5 Stocks to Buy as the Market Rally Broadens
-
4 Top US Travel Stock Picks
-
How Do Interest Rates Affect Stock Market Returns?
-
American Airlines Earnings: Ticket Distribution Misstep Affected Results
-
Going Into Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
3 Top Cybersecurity Stock Picks for Long-Term Investors
-
AbbVie Earnings: Firm Sees Strong Next-Generation Immunology Drugs Sales
-
Ford Earnings: Warranty Problems on Older Vehicles Slam Results
-
ServiceNow Earnings: Operating on a Higher Plane Within Enterprise Software